Business Wire2d
IMCAS 2025: New Galderma Phase IIIb Data Reinforce Rapid Onset and Long-lasting Aesthetic Improvement with RelabotulinumtoxinA (Relfydess™)
Galderma (SWX:GALD), the pure-play dermatology category leader, announced today results from its new phase IIIb RELAX ...
Morningstar2d
Galderma Group AG Registered Shares
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...